Summary of Bill S 3558
Bill 118 s 3558, also known as the Prohibiting Foreign Access to American Genetic Information Act of 2024, aims to protect the genetic information of American citizens from being accessed by foreign entities. The bill prohibits any foreign government, organization, or individual from obtaining or accessing genetic information of Americans without their explicit consent.
The legislation highlights the importance of safeguarding genetic data, as it contains sensitive and personal information that could be used for malicious purposes. By restricting foreign access to American genetic information, the bill seeks to prevent potential breaches of privacy and security.
Furthermore, the bill outlines strict penalties for those found in violation of the law, including hefty fines and potential imprisonment. It also establishes a framework for monitoring and enforcing compliance with the regulations set forth in the legislation.
Overall, the Prohibiting Foreign Access to American Genetic Information Act of 2024 is a proactive measure aimed at protecting the privacy and security of American citizens in an increasingly digital and interconnected world.
Congressional Summary of S 3558
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
Specifically, the bill prohibits executive agencies from (1) procuring or obtaining any biotechnology equipment or service produced or provided by a biotechnology company of concern, or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.
A biotechnology company of concern includes BGI, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of such entities, and any entity that
- is subject to the jurisdiction, direction, control, or operates on behalf of the government of a foreign adversary;
- is involved in the manufacturing, distribution, provision, or procurement of a biotechnology equipment or service; and
- poses a risk to U.S. national security based on specified activities.
Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.
The Office of Management and Budget must develop and periodically update a list of the entities that constitute biotechnology companies of concern.